Most cancer drugs work by slowly gumming up a cell’s machinery. NF27 takes a blunter approach: it punches holes in the cancer cell and makes it burst.
Researchers at Johns Hopkins described the peptide in the Journal of Medicinal Chemistry on October 23. It belongs to a class called oncolytic peptides, short chains of amino acids that rupture cancer cell membranes. No oncolytic peptide has been approved for clinical use yet.
The team started from CKS1, a 24-amino-acid peptide from their earlier work, and built a series of variants to see which design features mattered. Two stood out: a “hinge” created by a proline, and the way water-loving and water-repelling amino acids were arranged along the chain.
NF27 was the best of the bunch. In lab tests it killed many kinds of cancer cells, did little harm to healthy cells, and caused little damage to red blood cells. Dying cancer cells also seemed to sound an alarm, drawing immune cells into tumors in mice. In mouse tumor models, NF27 slowed tumor growth, wiped out some tumors completely, and caused no visible systemic toxicity.
A reality check: this is mouse data. Humans aren’t mice, and many promising compounds fail in later testing. The authors also hold a pending patent and co-founded a company around these peptides.
The part that sticks with us is that NF27 and its siblings are all close relatives. Move a proline, or rearrange a few residues, and you get a different molecule that behaves differently. In peptides, small details make the molecule.
That’s why identity and purity aren’t fine print. LC-MS confirms the mass matches the intended sequence, and HPLC shows how much of the vial is the target peptide and how much is something else.
Send us your sample today and verify the contents of your research compounds.
Sources
- Furukawa N, et al. “Discovery of a Highly Potent and Selective Oncolytic Peptide NF27 through Structure-Activity Relationship Studies.” Journal of Medicinal Chemistry, Oct 23, 2026. https://doi.org/10.1021/acs.jmedchem.6c02442
- Furukawa N, et al. “Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth.” Cell Death Discovery, 2024. https://doi.org/10.1038/s41420-024-01932-5